News from dnatrix A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Jan 13, 2020, 09:00 ET DNAtrix Appoints Jeff Knapp as Chief Executive Officer and to Board of Directors

DNAtrix, a leader in the development of oncolytic viruses for cancer therapy, announced today that Jeffrey Knapp has been appointed as Chief...

Nov 11, 2019, 09:00 ET DNAtrix to Present Updated Results from the Phase 2 CAPTIVE / KEYNOTE-192 Study of DNX-2401 in Combination with Pembrolizumab for Glioblastoma at the 2019 SNO Annual Meeting

DNAtrix, an oncolytic virus immunotherapy company with a proprietary adenovirus platform, today announced that updated data from the CAPTIVE /...

Nov 26, 2018, 09:00 ET DNAtrix's Oncolytic Virus Expressing OX40 Ligand Treats First Patient in Recurrent Glioblastoma Clinical Trial

DNAtrix, a leader in oncolytic virus immunotherapies for cancer, announced today the treatment of the first patient with DNX-2440, an oncolytic virus ...

Nov 15, 2018, 09:00 ET DNAtrix To Present Interim Phase 2 Results of DNX-2401 with Pembrolizumab for Glioblastoma

DNAtrix, a leader in oncolytic virus immunotherapies for cancer, will present interim results from the ongoing Phase 2 trial of its oncolytic virus...

Nov 13, 2018, 09:00 ET DNAtrix and Valo Therapeutics Enter into Strategic Partnership to Develop Peptide-Coated Oncolytic Viruses for Treating Cancer

DNAtrix and Valo Therapeutics today announced an exclusive R&D collaboration to develop enhanced vaccines using DNAtrix's clinical stage viruses and...

Nov 07, 2018, 16:00 ET Effectiveness of DNAtrix's DNX-2440 Oncolytic Virus Expressing OX40L in Solid Tumors to be Presented at the 2018 Annual Meeting of the Society for Immunotherapy of Cancer

DNAtrix, a leader in oncolytic virus immunotherapies for cancer, announced today that MD Anderson Cancer Center collaborator, Juan Fueyo, MD, will...

Jul 02, 2018, 09:00 ET Treatment of Pediatric Brain Tumor, DIPG, with Oncolytic Adenovirus DNX-2401 to be Presented at the 2018 International Symposium for Pediatric Neuro-Oncology

DNAtrix, a leader in oncolytic virus immunotherapies for cancer, announced today that Sonia Tejada, MD, PhD, neurosurgeon and investigator at Clínica ...

May 08, 2018, 09:00 ET Successful Delivery of DNAtrix's Oncolytic Virus DNX-2401 to Pediatric Brain Tumors

DNAtrix, a leader in oncolytic virus immunotherapies for cancer, announced that Sonia Tejada, MD, PhD, neurosurgeon and investigator at Clínica...

Apr 12, 2018, 09:00 ET Effectiveness of DNAtrix Oncolytic Virus DNX-2440 Armed with OX40L to be Presented at the 2018 Annual Meeting of the American Association for Cancer Research

DNAtrix, a leader in oncolytic virus immunotherapies for cancer, announced that DNAtrix collaborators will present results for an oncolytic virus...

Dec 05, 2017, 15:02 ET DNAtrix Announces First Pediatric Patient Treated with Oncolytic Virus DNX-2401

DNAtrix, a leader in the development of oncolytic virus immunotherapies for cancer, announced the intratumoral delivery of DNX-2401 to the first...

Nov 20, 2017, 08:00 ET Mechanism of Action Studies for DNAtrix's Oncolytic Virus DNX-2401 Presented at the 2017 Society for Neuro-Oncology Annual Meeting

DNAtrix, a leader in the development of oncolytic virus immunotherapies for cancer, announced multiple studies detailing the mechanism and efficacy...

Nov 13, 2017, 08:00 ET DNAtrix Virus Expressing T-Cell Co-stimulator OX40L (CD252) Presented at the 2017 Society for Immunotherapy of Cancer Meeting

Juan Fueyo, MD, Professor at MD Anderson Cancer Center Department of Neuro-Oncology, presented results of a comprehensive study on the oncolytic...

Jun 01, 2017, 16:00 ET DNAtrix to Present Results of DNX-2401 for Recurrent Glioblastoma at ASCO 2017

DNAtrix, a biopharmaceutical company developing oncolytic virus immunotherapies for cancer, announced today that it will present favorable safety and ...

May 11, 2017, 09:00 ET DNAtrix Oncolytic Myxoma Virus Eliminates Treatment-Resistant Cancer

DNAtrix, a clinical stage biotechnology company developing oncolytic viruses for cancer, today announced a podium presentation on the use of...

Apr 24, 2017, 09:00 ET Precision Intratumoral Delivery of DNX-2401 with the Alcyone MEMS Cannula

DNAtrix, a clinical stage biotechnology company developing virus-based immunotherapies for cancer, and Alcyone Lifesciences, a leader in neural...

Mar 30, 2017, 09:00 ET Antitumor Immunity Triggered by DNAtrix Armed Viruses to be Presented at the 2017 Annual Meeting of the American Association for Cancer Research

DNAtrix, a clinical stage biotechnology company developing virus-driven immunotherapies for cancer, today announced that results from four studies...

Nov 17, 2016, 04:00 ET DNAtrix to Present Clinical Data at the 21st Annual Meeting of the Society for Neuro-Oncology

DNAtrix, a clinical stage biotechnology company developing virus-driven immunotherapies for cancer, announced that two presentations updating safety...

Nov 08, 2016, 04:00 ET DNAtrix Licenses Myxoma Virus for New Immunotherapy Platform

DNAtrix, a clinical stage biotechnology company developing virus-driven immunotherapies for cancer, announced it has entered into an exclusive...

Nov 01, 2016, 04:00 ET DNAtrix Announces First Patients Treated in Phase 2 Trial with DNX-2401 and KEYTRUDA

DNAtrix, a clinical stage biotechnology company developing virus-driven immunotherapies for cancer, announced that the first patients have been...

Aug 04, 2016, 08:00 ET DNAtrix Awarded FDA Orphan Products Development Grant for DNX-2401

DNAtrix, a clinical stage biotechnology company developing virus-driven immunotherapies for cancer, announced the award of a $2 million research...

Jul 27, 2016, 12:40 ET DNAtrix Receives European Medicines Agency PRIME Designation

DNAtrix, a clinical stage biotechnology company developing virus-driven immunotherapies for cancer, announced that the European Medicines Agency...

Jul 21, 2016, 09:00 ET DNAtrix Announces Successful Intratumoral Delivery of DNX-2401 via Alcyone's MEMS Cannula for the Targeted Treatment of Recurrent Glioblastoma

DNAtrix, a clinical stage, biotechnology company developing virus-driven immunotherapies for cancer, announced the successful intratumoral...

Feb 09, 2016, 09:00 ET DNAtrix's Oncolytic Immunotherapy, DNX-2401, Awarded EU Orphan Medicine Designation for Treating Malignant Brain Tumors

DNAtrix, a clinical stage, biotechnology company developing virus-driven immunotherapies for cancer, announced that its lead product, DNX-2401, has...